We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC (EMERALD-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05611671
Recruitment Status : Recruiting
First Posted : November 10, 2022
Last Update Posted : January 26, 2023
Sponsor:
Information provided by (Responsible Party):
Morphic Therapeutic, Inc

Brief Summary:
This is a Phase 2b randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of three active dose regimens of MORF-057 in adult patients with moderately to severely active Ulcerative Colitis (UC).

Condition or disease Intervention/treatment Phase
Inflammatory Bowel Diseases Colitis, Ulcerative Drug: MORF-057 Drug: Placebo Phase 2

Detailed Description:
This is a Phase 2b randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of three active dose regimens of MORF-057 plus a placebo regimen in study participants with moderately to severely active UC. After completion of the 12-week Induction Period, participants may be switched to a different active MORF-057 regimen during the Maintenance Period. Those randomized into the placebo group in the Induction Period will be switched to receive an active MORF-057 regimen during the Maintenance Period.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 280 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of 3 Active Dose Regimens of MORF-057 in Adults With Moderately to Severely Active Ulcerative Colitis (EMERALD-2)
Actual Study Start Date : October 31, 2022
Estimated Primary Completion Date : May 2025
Estimated Study Completion Date : July 2025

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Group 1
MORF-057 Dosing Regimen One for Induction and Maintenace Periods
Drug: MORF-057
MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.

Experimental: Group 2
MORF-057 Dosing Regimen Two for Induction and Maintenace Periods
Drug: MORF-057
MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.

Experimental: Group 3
MORF-057 Dosing Regimen Three for Induction and Maintenace Periods
Drug: MORF-057
MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.

Placebo Comparator: Group 4
Matching Placebo Dosing Regimen for Induction and MORF-057 Dosing Regimen Four for Maintenance
Drug: MORF-057
MORF-057 is a small molecule that is designed to selectively inhibit integrin α4β7 and is administered orally.

Drug: Placebo
Matching placebo (identical appearance to MORF-057) administered orally.




Primary Outcome Measures :
  1. Proportion of participants in clinical remission at Week 12 as determined using the Modified Mayo Clinic Score (mMCS). [ Time Frame: From baseline to 12 weeks ]
    mMCS is a composite of the Mayo endoscopic and Mayo clinic scores, and stool frequency scores.


Secondary Outcome Measures :
  1. Change from baseline to Week 12 in clinical response in the Modified Mayo Clinic Score (mMCS) [ Time Frame: From baseline to 12 weeks ]
    mMCS is a composite of the Mayo endoscopic and Mayo clinic scores, and stool frequency scores.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Has signs/symptoms of moderate to severe UC for at least 3 months prior to Screening
  • Has evidence of UC extending at least 15 cm from the anal verge
  • Demonstrated an inadequate response, loss of response, or intolerance to at least one of the following treatments: Oral aminosalicylates (e.g., mesalamine, sulfasalazine, olsalazine, or balsalazide), corticosteroids, immunosuppressants (e.g., azathioprine, 6-mercaptopurine, or methotrexate), advanced therapies for UC (e.g., biologic agents, Janus kinase [JAK] antagonists, or sphingosine-1-phosphate [S1P] receptor agonists)
  • Subject has no prior exposure to approved or investigational anti-integrin therapies
  • Agrees to abide by the study guidelines and requirements
  • Capable of giving signed informed consent

Exclusion Criteria:

  • Diagnosed with indeterminate colitis, microscopic colitis, ischemic colitis, radiation colitis, or Crohn's disease or has clinical findings suggestive of Crohn's disease
  • Has positive findings on a subjective neurological screening questionnaire
  • Has a concurrent, clinically significant, serious, unstable comorbidity
  • Previous treatment with vedolizumab or other licensed or investigational integrin inhibitors
  • Participation in any other interventional study or received any investigational therapy within 30 days
  • Previous exposure to MORF-057 and/or a known hypersensitivity to drugs with a similar mechanism to MORF-057
  • Unable to attend study visits or comply with study procedures

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05611671


Contacts
Layout table for location contacts
Contact: Morphic Therapeutic, Inc 781-996-0955 clinicaltrials@morphictx.com

Locations
Layout table for location information
United States, Arizona
Clinical Study Site Recruiting
Sun City, Arizona, United States, 85351
United States, California
Clinical Study Site Recruiting
Lancaster, California, United States, 93534
United States, Florida
Clinical Study Site Recruiting
Kissimmee, Florida, United States, 34741
Clinical Study Site Recruiting
Miami, Florida, United States, 33175
Clinical Study Site Recruiting
Miramar, Florida, United States, 33027
Clinical Study Site Recruiting
Orlando, Florida, United States, 32803
United States, Kansas
Clinical Study Site Recruiting
Wichita, Kansas, United States, 67226
United States, Massachusetts
Clinical Study Site Recruiting
Boston, Massachusetts, United States, 02215
United States, New Jersey
Clinical Study Site Recruiting
Freehold, New Jersey, United States, 07728
United States, Ohio
Clinical Study Site Recruiting
Mentor, Ohio, United States, 44060
United States, South Carolina
Clinical Study Site Recruiting
Greenville, South Carolina, United States, 29605
United States, Texas
Clinical Study Site Recruiting
Austin, Texas, United States, 78748
Clinical Study Site Recruiting
Cedar Park, Texas, United States, 78613
Australia
Clinical Study Site Not yet recruiting
Perth, Australia, 6150
Sponsors and Collaborators
Morphic Therapeutic, Inc
Layout table for additonal information
Responsible Party: Morphic Therapeutic, Inc
ClinicalTrials.gov Identifier: NCT05611671    
Other Study ID Numbers: MORF-057-202
First Posted: November 10, 2022    Key Record Dates
Last Update Posted: January 26, 2023
Last Verified: January 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Morphic Therapeutic, Inc:
Ulcerative Colitis (UC)
Inflammatory Bowel Disease (IBD)
a4b7
Moderate-to-severe
Integrin
EMERALD
Additional relevant MeSH terms:
Layout table for MeSH terms
Colitis
Intestinal Diseases
Inflammatory Bowel Diseases
Colitis, Ulcerative
Ulcer
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Colonic Diseases
Pathologic Processes